Latest Research
All publications from the Cancer3.AI database, newest first.
Manganese-activatable nano-hydroxyapatite nanoparticles as self-adjuvanting STING activators for synergistic melanoma therapy.
Xiang S, et al
Researchers developed a novel nanoparticle platform called nHA-Mn, based on nano-hydroxyapatite modified with manganese, designed to simultaneously kill melanoma cells directly and stimulate the immune system to fight the tumor. The platform is engineered to release calcium and manganese ions selectively in the acidic environment of tumors, triggering mitochondrial dysfunction and cell death while also activating the STING immune pathway, which coordinates a broad anti-tumor immune response. In laboratory and animal studies, nHA-Mn promoted the maturation of dendritic cells, increased the infiltration of cancer-fighting CD4+ and CD8+ T cells into tumors, and elevated levels of the immune signaling molecule IFN-γ, collectively enhancing the body's ability to recognize and destroy cancer cells. Notably, the treatment also induced the formation of immune memory T cells, suggesting the potential for long-term protection against tumor recurrence, all while demonstrating a favorable safety profile. This work is significant because it addresses the major clinical problem of immunosuppressive tumor microenvironments in melanoma, which frequently cause conventional therapies to fail. By combining direct cytotoxicity with self-adjuvanting immune activation in a single biocompatible nanoplatform, nHA-Mn represents a promising next-generation strategy for cancer immunotherapy.
Journal of materials chemistry. B
Source →Malignant Melanoma With Rhabdomyosarcomatous Differentiation: Report of 2 New Cases.
Daruish M, et al
Researchers from the field of dermatopathology report two new cases of a rare and aggressive form of skin cancer in which malignant melanoma — the deadliest type of skin cancer — acquires features normally associated with rhabdomyosarcoma, a cancer of skeletal muscle tissue. This unusual combination, known as divergent differentiation, is exceptionally rare and creates major challenges for pathologists trying to reach an accurate diagnosis. The study emphasizes that thorough tissue sampling and the use of specialized skeletal muscle protein stains (immunohistochemistry) are critical steps when tumor cells display a so-called rhabdoid appearance under the microscope. Recognizing this rare variant matters greatly for clinicians because it signals a particularly aggressive disease course, which may influence treatment decisions and patient prognosis. These case reports add to the limited medical literature on this phenomenon and provide practical diagnostic guidance for pathologists encountering similar presentations in the future.
The American Journal of dermatopathology
Source →Personal medical history, family history of cancer and the risk of soft tissue sarcoma.
Turati F, et al
Researchers from Italy conducted a case-control study to investigate whether personal medical history and family history of cancer are associated with the risk of developing soft tissue sarcoma (STS), a rare and poorly understood cancer of muscles, fat, nerves, and connective tissues. The study included 498 confirmed STS patients and 969 hospital controls, analyzing self-reported health histories using advanced statistical methods. Key findings revealed that a history of burns more than doubled the risk of STS, while a suggestive but statistically uncertain link was observed with herpes zoster (shingles) infection. Interestingly, patients with hypertension, high cholesterol, or prior tonsillectomy appeared less likely to develop STS, though the reasons for these inverse associations remain unclear. Family history of STS itself and of kidney cancer were both associated with elevated STS risk, pointing to possible hereditary or shared environmental factors. These results highlight burns and viral infections as potential areas for further investigation, while also reinforcing that genetic predisposition may play a role in a subset of STS cases.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Source →Are Myeloproliferative Neoplasms-Unclassifiable Really Unclassifiable?
Barosi G, et al
Myeloproliferative neoplasms-unclassifiable (MPN-U) is a diagnostic category assigned to patients whose blood cancer does not clearly fit into the established subtypes of polycythemia vera, essential thrombocythemia, or primary myelofibrosis. This study investigated whether patients labeled as MPN-U truly represent an indeterminate group or whether more rigorous clinical, morphological, and molecular evaluation could reclassify them into defined MPN subtypes. The findings suggest that a substantial proportion of cases initially deemed unclassifiable can in fact be assigned to recognized disease categories when advanced diagnostic criteria and genetic testing are systematically applied. This has meaningful implications for patient care, as accurate classification drives treatment decisions, prognostic counseling, and eligibility for targeted therapies. Clinicians are encouraged to pursue thorough re-evaluation of MPN-U diagnoses rather than accepting the unclassifiable label as final, potentially improving outcomes for affected patients.
EJHaem
Source →A tumor suppressor role of the miR-15b/16-2 cluster in T-cell acute lymphoblastic leukemia.
Toribio ML, et al
Researchers investigated the role of microRNAs — small molecules that regulate gene activity — in T-cell acute lymphoblastic leukemia (T-ALL), an aggressive blood cancer that develops from immature immune cells and currently lacks effective targeted treatments. By mapping microRNA activity across normal human T-cell development, the team identified a cluster of two microRNAs, miR-15b and miR-16-2, that rise and fall in a precise pattern during the maturation of T cells in the thymus. Functional experiments showed that this miR-15b/16-2 cluster acts as a brake on cell growth: when artificially restored in leukemia cells, it suppressed cancer cell proliferation in the laboratory and slowed tumor progression in mouse models transplanted with patient-derived leukemia cells. Mechanistically, the cluster works by dampening the activity of BCL-2, a protein that helps cancer cells evade death, and CYCLIN D3, a protein that drives cell division, ultimately trapping leukemic cells in a non-dividing state and preventing them from completing the cell cycle. These findings establish miR-15b/16-2 as a tumor suppressor in T-ALL and open a new avenue for therapeutic strategies aimed at restoring its activity in patients with this difficult-to-treat leukemia.
Blood
Source →